Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




May
29
Today In Oncology
ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial
Behind the Scenes of the 2026 ASCO Annual Meeting
First-Line Sunvozertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations
FDA Approves Durvalumab Plus BCG for High-Risk NMIBC
Local Radiotherapy May Help Control Oligometastatic Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo